- Home
- LTRN
LTRN
Lantern Pharma Inc.
as 05-14-2025 9:39am EST
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Upcoming Earnings Alert:
Get ready for potential market movements as Lantern Pharma Inc. LTRN prepares to release earnings report on 15 May 2025.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 37.2M | IPO Year: | 2020 |
| Target Price: | $25.00 | AVG Volume (30 days): | 37.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.55 - $7.21 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Lantern Pharma Inc. News
LTRN Breaking Stock News: Dive into LTRN Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
Benzinga
2 days ago
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Business Wire
6 days ago
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
Zacks Small Cap Research
8 days ago
LTRN: IND Clearance for LP-184 in TNBC
Business Wire
9 days ago
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
Benzinga
9 days ago
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
GuruFocus.com
a month ago
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges
Zacks Small Cap Research
2 months ago
LTRN: 2024 Financial Results
Compare LTRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LTRN Lantern Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.